MiNK-201
Acute Respiratory Distress Syndrome (ARDS)
Phase 1b/2Active
Key Facts
Indication
Acute Respiratory Distress Syndrome (ARDS)
Phase
Phase 1b/2
Status
Active
Company
About MiNK Therapeutics
MiNK Therapeutics is advancing a first-in-class, allogeneic iNKT cell therapy platform with the mission to deliver effective, readily available 'living medicines' for oncology and inflammatory diseases. The company has demonstrated initial clinical proof-of-concept, having treated over 70 patients across its programs in solid tumors and ARDS, and is leveraging the inherent safety and versatility of iNKT cells to build a pipeline of off-the-shelf products. Its strategy focuses on validating its lead assets, expanding into new indications through strategic combinations, and pioneering next-generation engineered iNKT cells to enhance targeting and persistence.
View full company profileTherapeutic Areas
Other Acute Respiratory Distress Syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| BXT-25 | BioXyTran | Preclinical |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| FX06 | F4 Pharma | Phase 1/2 |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| RP-323 | PhorMed | Phase 2 |
| Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS | Sedana Medical | Investigator-Initiated Trial |